Loading
A phase 1 trial of CBA-1205 run by Chiome Bioscience Inc., now recruiting.
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer is a phase 1 interventional study registered as NCT06636435 by Chiome Bioscience Inc., with 66 participants planned, started 2020-06-01. Conditions recorded: Solid Tumors, Hepatocellular Carcinoma (HCC), Malignant Melanoma and Pediatric Cancer. Interventions recorded: CBA-1205 Part 1, CBA-1205 Part 2, CBA-1205 Part 3, CBA-1205 Part 4 and CBA-1205 Part 5.
Shares Chiome Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Chiome Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Chiome Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Chiome Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Chiome Bioscience and the tag pipeline.
Shares Hepatocellular carcinoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Hepatocellular carcinoma, Melanoma and the tag pipeline.
Shares Hepatocellular carcinoma, Melanoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/